Acute decompensation of chronic heart failure
Conditions
Interventions
Conventional-dose recombinant human brain natriuretic peptide group:Conventional dose group: On the basis of conventional treatment, recombinant human brain natriuretic peptide at a dose of 0.0075-0.0
High-dose recombinant human brain natriuretic peptide group:On the basis of conventional treatment, continuous intravenous infusion of Xinhuosu at a dose of 0.015-0.02µg/kg·min is administered for 5 t
Sponsors
Tianjin Chest Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >=18 years old; 2.NYHA cardiac function classification grade ? to ?; 3.Patients diagnosed with acute decompensation of chronic heart failure within no more than 48 hours and with diuretic resistance; The diagnostic criteria for diuretic resistance refer to the "2024 Chinese Expert Consensus on the Diagnosis and Management of Diuretic Resistance in Heart Failure Patients" : Unsatisfactory water and sodium excretion after the use of loop diuretics affects the regulation of volume load. Even after daily intravenous administration of furosemide at a dose of =80mg or equivalent doses of other diuretics, the appropriate urine volume (1.0mL/kg/ h) still cannot be achieved. The conversion formulas for different loop diuretics are as follows: Oral furosemide 80mg= intravenous furosemide 40mg= oral/intravenous torasemide 20mg= oral/intravenous bumetanide 1 mg. 4.Elevated levels of brain natriuretic peptide (BNP) or N-terminal pro-brain natriuretic peptide (NT-proBNP), with BNP>=400 pg/ml or NT-proBNP >=1200 pg/ml 5.They were willing to participate in the trial and signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Those with an expected hospitalization time of no more than 24 hours; 2. Those with hypotension or a significant risk of hypotension (persistent systolic blood pressure 2.5 times ULN; 5. Those who are pregnant, breastfeeding or planning to get pregnant within three months; 6. Those who are known or suspected of being allergic to the test product or its components; 7. Participated in other researchers within the past month; 8. Any other conditions that the researchers consider may pose a risk to the patient.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The readmission rate for heart failure within 30 days; | — |
Countries
China
Contacts
Public ContactJinping Feng
Tianjin Chest Hospital
Outcome results
None listed